After initial setback, IL-12 regaining popularity.
Jenks
S
S
D004334:Drug Administration Schedule; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D018664:Interleukin-12 / Q000008:administration & dosage / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D014481:United States; D014486:United States Food and Drug Administration
D018664:Interleukin-12